Clinical experiences with dibromodulcitol (NSC-104800) in solid tumors.
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000009:adverse effects*; D001966:Bromine / Q000009:adverse effects; D001984:Bronchial Neoplasms / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic; D005260:Female; D004376:Galactitol / Q000009:adverse effects; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D013402:Sugar Alcohols / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000139:chemically induced
D000477:Alkylating Agents; D013402:Sugar Alcohols; D004376:Galactitol; D001966:Bromine